Shares of Natco Pharma Ltd were trading 3% higher on Friday, 17 October, after the Supreme Court (SC) quashed a plea from Roche, which was challenging the interim Delhi High Court Order for rolling out the generic version of the Risdipalm.

The Supreme Court ruled that there was no justification to interfere with the Delhi High Court’s interim order and therefore declined to restrict Natco Pharma from selling or exporting the generic version of Risdipalm.

The Apex Court also instructed the Delhi High Court to expedite the hearing of the Roche–Natco dispute.

Following this verdict, Natco Pharma can now market its Spinal Muscular Atrophy treatment drug at Rs 15,900, a significant reduction from Roche’s imported price of Rs 6 lakh, marking a major victory for patients. Both Roche’s Risdipalm and Natco’s generic version are available in 60 mg / 80 ml bottles.

Risdipalm, developed by Roche, is used to treat Spinal Muscular Atrophy. The company had earlier approached the Supreme Court challenging the Delhi High Court’s order, which permitted Natco Pharma to sell its generic version of the drug.

At 2:25 pm, the shares of Natco Pharma were trading 1.42% higher at Rs 833.50 on NSE.

Tired of missing hot stocks? Unicorn Signals provides powerful tools like stock scans and more help you make informed trading decisions. Download now and take control of your portfolio!